Evidence map›Paper›PMID 32016459›Full record

ArticleMolecular medicine reports2020

Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells.

Francesca Cammarota, Andrea Conte, Antonietta Aversano, Paolo Muto, Gianluca Ametrano, Patrizia Riccio, Mimmo Turano, Valeria Valente, Paolo Delrio, Paola Izzo and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Lithium: A Promising Anticancer Agent.Life (Basel, Switzerland) · 2023
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Nitrodi thermal water downregulates protein S‑nitrosylation in RKO cells.International journal of molecular medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Francesca Cammarota *Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I‑80131 Naples, Italy.
Andrea Conte *Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I‑80131 Naples, Italy.
Antonietta AversanoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I‑80131 Naples, Italy.
Paolo MutoRadiation Oncology, Istituto Nazionale Tumori‑IRCCS Fondazione G. Pascale, I‑80131 Naples, Italy.
Gianluca AmetranoRadiation Oncology, Istituto Nazionale Tumori‑IRCCS Fondazione G. Pascale, I‑80131 Naples, Italy.
Patrizia RiccioDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I‑80131 Naples, Italy.
Mimmo TuranoDepartment of Biology, University of Naples Federico II, I‑80126 Naples, Italy.
Valeria ValenteDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I‑80131 Naples, Italy.
Paolo DelrioDepartment of Abdominal Oncology, Colorectal Surgical Oncology Unit, Istituto Nazionale Tumori‑IRCCS Fondazione G. Pascale, I‑80131 Naples, Italy.
Paola IzzoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I‑80131 Naples, Italy.
Giovanna Maria Pierantoni *Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I‑80131 Naples, Italy.
Marina De Rosa *Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I‑80131 Naples, Italy.
University of Naples Federico II · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide. It is also the second most common cause of cancer‑associated mortality; it accounted for about 9.2% of all cancer deaths in 2018, most of which were due to resistance to therapy. The main treatment for CRC is surgery, generally associated with chemotherapy, radiation therapy and combination therapy. However, while chemo‑radiotherapy kills differentiated cancer cells, mesenchymal stem‑like cells are resistant to this treatment, and this can give rise to therapy‑resistant tumors. Our previous study isolated T88 primary colon cancer cells from a patient with sporadic colon cancer. These cells exhibited mesenchymal and epithelial features, high levels of epithelial‑to‑mesenchymal transition transcription factors, and stemness markers. In addition, it was revealed that lithium chloride (LiCl), a specific glycogen synthase kinase (GSK)‑3β inhibitor, induced both the mesenchymal‑to‑epithelial transition and differentiation, and also reduced cell migration, stemness features and cell plasticity in these primary colon cancer cells. The aim of the present study was to investigate the effect of LiCl treatment on the viability of primary colon cancer cells exposed to 7 Gy delivered by high‑energy photon beams, which corresponds to 6 megavolts of energy. To achieve this aim, the viability of irradiated T88 cells was compared with that of irradiated T88 cells pre‑treated with LiCl. As expected, it was observed that LiCl sensitized primary colon cancer cells to high‑energy photon irradiation treatment. Notably, the decrease in cell viability was greater with combined therapy than with irradiation alone. To explore the molecular basis of this response, the effect of LiCl on the expression of Bax, p53 and Survivin, which are proteins involved in the apoptotic mechanism and in death escape, was analyzed. The present study revealed that LiCl upregulated the expression of pro‑apoptotic proteins and downregulated the expression of proteins involved in survival. These effects were enhanced by high‑energy photon irradiation, suggesting that LiCl could be used to sensitize colon cancer cells to radiation therapy.

Indexed as

PhotonsApoptosisCell Line, TumorCell ProliferationCell SurvivalColonic NeoplasmsHumansLithium ChlorideRadiation-Sensitizing AgentsRadiation ToleranceRadiotherapy, High-EnergySignal TransductionLithium ChlorideRadiation-Sensitizing Agentsapoptosiscancer drug resistancehigh energy photon irradiationlithium chloridemesenchymal colon cancer cells

Identifiers

PMID32016459
PMCPMC7002976
OpenAlexW3002517466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.